Trials: Partial Seizures

Phase 4 N=102 A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset Seizures

Epilepsy With Partial On-set Seizures

Primary: The Number of Subjects Completing 24 Weeks Adjunctive Therapy During Maintenance Phase — 36; 37 participants

Sumitomo Pharma America, Inc. Results Jun 2020 3.9% serious AE View details

Phase 3 N=509 Pregabalin Versus Levetiracetam In Partial Seizures

Partial Seizures

Primary: Proportion of Participants With Response to Treatment — 0.59; 0.59 proportion of participants

Pfizer's Upjohn has merged with Mylan to form… Results Jul 2013 9.4% serious AE View details

Phase 3 N=323 Once-A-Day Pregabalin For Partial Seizures

Partial Seizures · Epilepsies, Partial

Primary: Log Transformed (Loge) 28-day Seizure Rate for All Partial Onset Seizures During the Double-blind Treatment Phase — 2.24; 2.33; 2.32; 1.84 ln (seizures per 28 days)…

Pfizer's Upjohn has merged with Mylan to form… Results Jun 2018 3.7% serious AE View details

Phase 2 N=31 Study With Seletracetam (Ucb 44212) in Adult Subjects (18 to 65 Years) With Partial Onset Seizures

Epilepsy, Partial

Primary: Percentage Change From Baseline in Seizure Frequency Per Week of Partial Onset Seizures (Type I) During the Up-titration Period — -30.88 percentage of change

UCB S.A. - Pharma Sector Results Mar 2024 0.0% serious AE View details

Phase 3 N=180 Perampanel as Adjunctive Therapy in Pediatrics With Partial Onset Seizures or Primary Generalized Tonic Clonic Seizures

Partial-Onset or Primary Generalized Tonic-Clonic Seizures

Primary: Percentage of Participants With Treatment Emergent Adverse Events (AEs) and Treatment Emergent Serious Adverse Events (SAEs) for Total Group of Participants - Core Phase…

Eisai Inc. Results Apr 2020 19.8% serious AE View details

Phase 4 N=106 Trial Evaluating the Efficacy and Safety of Perampanel Added to Monotherapy in Participants With Partial Onset Seizures With or Without Secondary Generalization

Epilepsy

Primary: 50 Percent (%) Responder Rate for Partial Onset Seizure With or Without Secondary Generalization — 80.0 percentage of participants

Eisai Korea Inc. Results Feb 2020 7.8% serious AE View details

Phase 3 N=75 Extension Study Of Long-Term Safety And Efficacy Of Pregabalin As Monotherapy (Lyrica) In Patients With Partial Seizures

Epilepsy

Primary: Seizure Frequency

Pfizer's Upjohn has merged with Mylan to form… Results Sep 2012 4.1% serious AE View details

Phase 2 N=222 Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures

Partial Epilepsy

Primary: Percent Change From Baseline in Partial-onset Seizure Frequency Per 28 Days — 55.6; 21.5 percent seizure reduction — p=<0.0001

SK Life Science, Inc. Results Apr 2022 3.2% serious AE View details

Phase 4 N=54 Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures

Partial Onset Seizures · Secondarily Generalized Seizures · Primary Generalized Tonic-Clonic Seizures

Primary: Percentage of Participants Remaining on Perampanel Treatment at 3 Months After the Initiation of Treatment — 85.2 percentage of participants

Eisai Inc. Results May 2022 7.4% serious AE View details

Phase 3 N=768 Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures

Epilepsy

Primary: Percent Reduction Over Placebo for Partial Onset Seizure (Type I) Frequency Over the Treatment Period Standardized to a 28-day Duration — 22.8; 23.2; 0 Percentage of…

UCB Pharma Results Aug 2016 3.3% serious AE View details

Phase 2 N=65 Safety, Tolerability, and Pharmacokinetic Study of Pregabalin in Pediatric Patients With Partial Onset Seizures

Epilepsies, Partial

Primary: Number of Treatment-Emergent Adverse Events (AEs) by Severity: Double-blind Treatment — 0; 2; 2; 4 adverse events

Pfizer's Upjohn has merged with Mylan to form… Results Mar 2014 3.1% serious AE View details

Phase 4 N=187 Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo

Epilepsies, Partial

Primary: Percentage of Participants With a Decrease (p<0.05) From Baseline in Threshold Value in Any 5 or More Points in Humphrey 24-2 Swedish Interactive Threshold Algorithm…

Pfizer's Upjohn has merged with Mylan to form… Results Feb 2021 2.7% serious AE View details

N/A N=31 Cognitive Effects of Treatment of Interictal Discharges

Epilepsy

Primary: Mean Change in Focal Interictal Discharges (IEDs) Per Hour, Pre to Post Treatment — -28.8; .54 IEDs/hour — p=>0.05

Massachusetts General Hospital Results Aug 2018 0.0% serious AE View details

Phase 3 N=91 Study for Verification of Efficacy and Safety for Perampanel Monotherapy in Untreated Participants With Partial Onset Seizures (Including Secondarily Generalized Seizures (FREEDOM Study)

Partial Onset Seizures

Primary: Percentage of Participants With Partial-onset Seizures (POS) Who Achieved Seizure-free Status During the 26-week Maintenance Period of 4 mg Perampanel — 63.0 percentage…

Eisai Co., Ltd. Results Feb 2020 14.6% serious AE View details

Phase 3 N=64 A Study for Evaluating the Efficacy and Safety of Zonisamide and Lamotrigine (Lamictal) for Subjects With Refractory Simple Partial, Complex Partial or Partial With Secondary Generalized Seizures

Epilepsy

Primary: The Percentage Change of Monthly Seizure Frequency at the End of the 16-week Treatment From Baseline — -32.7; -35.6 percent change — p=0.240

Eisai Inc. Results Aug 2011 1.6% serious AE View details

Phase 2 N=437 A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures

Partial Epilepsy

Primary: Percent Change From Baseline in Partial-onset Seizure Frequency Per 28 Days — -24.0; -35.5; -55.0; -55.0 percent change — p=<0.001

SK Life Science, Inc. Results Apr 2022 13.5% serious AE View details

Phase 3 N=249 Study to Evaluate the Safety and Effectiveness of USL255 in Patients With Refractory Partial-onset Seizures

Epilepsy

Primary: Percent Reduction From Baseline in Weekly (7 Day) Partial-onset Seizure Frequency During the Titration Plus Maintenance Phase Compared to Baseline. — 39.5; 21.65 Percent…

Upsher-Smith Laboratories Results May 2014 1.6% serious AE View details

Phase 2 N=147 A Randomized, Controlled Trial of Ganaxolone in Adult Uncontrolled Partial-Onset Seizures

Partial Epilepsy · Catamenial Epilepsy

Primary: Mean Weekly Log-transformed Seizure Frequency During Weeks 1 Through 10 — 5.20; 10.77 log[seizures per week]

Marinus Pharmaceuticals Results Mar 2023 6.1% serious AE View details

Phase 3 N=163 A Efficacy and Safety Study of Adjunctive Perampanel in Primary Generalized Tonic Clonic Seizures

Seizure Disorder Generalized Tonic Clonic

Primary: Median Percent Change in Primary Generalized Tonic Clonic Seizure Frequency (PGTC) Per 28 Days During the Titration and Maintenance Periods (Combined) Relative to…

Eisai Inc. Results Jan 2016 10.3% serious AE View details

Phase 3 N=219 A Safety, Efficacy and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric and Adult Subjects With Primary Generalized Tonic-Clonic (i.e., Grand Mal) Seizures.

Generalized Tonic Clonic Seizures

Primary: Log-transformed (Log) 28-day Seizure Rate for All Primary Generalized Tonic-Clonic (PGTC) Seizures During 12-Week Double-Blind Treatment Phase — 1.17; 1.13; 1.14 Seizure…

Pfizer's Upjohn has merged with Mylan to form… Results Aug 2019 3.2% serious AE View details

Phase 3 N=240 RNS® System Pivotal Study

Epilepsy

Primary: Acute SAE Rate — 12.0 percentage of subjects with ≥ 1 SAE

NeuroPace Results Aug 2013 52.9% serious AE View details

Phase 3 N=399 Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures

Epilepsy

Primary: Partial Onset Seizure (Type I) Frequency Per Week Over the 12-week Treatment Period — 1.75; 1.34; 1.49; 1.26 Seizure Frequency per Week — p==0.261

UCB Pharma SA Results Apr 2016 3.5% serious AE View details

Phase 4 N=482 Comparative Study Of Pregabalin And Gabapentin As Adjunctive Therapy In Subjects With Partial Seizures

Epilepsy · Partial Seizure Disorder · Epilepsies, Partial

Primary: Percent Change From Baseline in 28-day Seizure Frequency at Week 21. — -58.65; -57.43 percent change — p=0.8708

Pfizer's Upjohn has merged with Mylan to form… Results Aug 2014 5.6% serious AE View details

Phase 3 N=400 Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures

Epilepsy

Primary: Partial Onset Seizure (Type I) Frequency Per Week Over the 12-week Treatment Period — 2.15; 1.80; 1.96; 1.70 seizures per week — p==0.025

UCB Pharma Results Apr 2016 2.0% serious AE View details

Phase 2 N=21 A Study of Intravenous Perampanel in Japanese Participants With Epilepsy

Epilepsy · Seizures

Primary: Number of Participants With Serious Adverse Events (SAEs) — 0; 1; 2 Participants

Eisai Co., Ltd. Results Jan 2021 4.8% serious AE View details

Phase 3 N=251 A Double-blind, Placebo-controlled Study of Levetiracetam in Epilepsy Patients With Generalized Tonic-clonic Seizures (Except Partial Seizures Evolving to Secondarily Generalized Seizures)

Epilepsy · Generalized Tonic-Clonic Seizures

Primary: Percentage Change From the Combined Baseline in the Generalized Tonic-clonic Seizure Frequency Per Week Over the 28-week Treatment Period (Dose Adjustment + Evaluation…

UCB Japan Co. Ltd. Results May 2015 2.0% serious AE View details

Phase 3 N=390 Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

Refractory Partial Seizures

Primary: Percent Change in the 28-day Seizure Frequency From Baseline to the End of the Double-blind Phase (Titration and Maintenance Phases) — -20.95; -26.34; -34.49 Percent…

Eisai Inc. Results Feb 2013 5.9% serious AE View details

Phase 3 N=605 A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures

Epilepsy, Partial Seizures · Epilepsy, Primary Generalized Tonic-Clonic Seizures

Primary: Number of Participants With Treatment Emergent Adverse Events (AEs), Treatment Emergent Serious Adverse Events (SAEs), Treatment Related AEs and Treatment Related SAEs…

Pfizer's Upjohn has merged with Mylan to form… Results Feb 2020 12.7% serious AE View details

Phase 4 N=38 Treatments for Psychogenic Nonepileptic Seizures (NES)

Convulsion, Non-Epileptic · Conversion Disorder · Depression

Primary: Number of Nonepileptic Seizures (NES) — 5.0; 6.0; 3.0; 6.0 seizures — p=0.29

Rhode Island Hospital Results Jan 2011 0.0% serious AE View details

Phase 3 N=712 Evaluating Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

Refractory Partial Seizures

Primary: Percent Change in the 28-day Seizure Frequency From Baseline to the End of the Double-blind Phase (Titration and Maintenance Phases) — -10.69; -13.63; -23.33; -30.80…

Eisai Inc. Results Nov 2012 3.8% serious AE View details

Clinical Trial Search

Phase 4 N=102 A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset Seizures

Phase 3 N=509 Pregabalin Versus Levetiracetam In Partial Seizures

Phase 3 N=323 Once-A-Day Pregabalin For Partial Seizures

Phase 2 N=31 Study With Seletracetam (Ucb 44212) in Adult Subjects (18 to 65 Years) With Partial Onset Seizures

Phase 3 N=180 Perampanel as Adjunctive Therapy in Pediatrics With Partial Onset Seizures or Primary Generalized Tonic Clonic Seizures

Phase 4 N=106 Trial Evaluating the Efficacy and Safety of Perampanel Added to Monotherapy in Participants With Partial Onset Seizures With or Without Secondary Generalization

Phase 3 N=75 Extension Study Of Long-Term Safety And Efficacy Of Pregabalin As Monotherapy (Lyrica) In Patients With Partial Seizures

Phase 2 N=222 Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures

Phase 4 N=54 Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures

Phase 3 N=768 Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures

Phase 2 N=65 Safety, Tolerability, and Pharmacokinetic Study of Pregabalin in Pediatric Patients With Partial Onset Seizures

Phase 4 N=187 Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo

N/A N=31 Cognitive Effects of Treatment of Interictal Discharges

Phase 3 N=91 Study for Verification of Efficacy and Safety for Perampanel Monotherapy in Untreated Participants With Partial Onset Seizures (Including Secondarily Generalized Seizures (FREEDOM Study)

Phase 3 N=64 A Study for Evaluating the Efficacy and Safety of Zonisamide and Lamotrigine (Lamictal) for Subjects With Refractory Simple Partial, Complex Partial or Partial With Secondary Generalized Seizures

Phase 2 N=437 A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures

Phase 3 N=249 Study to Evaluate the Safety and Effectiveness of USL255 in Patients With Refractory Partial-onset Seizures

Phase 2 N=147 A Randomized, Controlled Trial of Ganaxolone in Adult Uncontrolled Partial-Onset Seizures

Phase 3 N=163 A Efficacy and Safety Study of Adjunctive Perampanel in Primary Generalized Tonic Clonic Seizures

Phase 3 N=219 A Safety, Efficacy and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric and Adult Subjects With Primary Generalized Tonic-Clonic (i.e., Grand Mal) Seizures.

Phase 3 N=240 RNS® System Pivotal Study

Phase 3 N=399 Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures

Phase 4 N=482 Comparative Study Of Pregabalin And Gabapentin As Adjunctive Therapy In Subjects With Partial Seizures

Phase 3 N=400 Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures

Phase 2 N=21 A Study of Intravenous Perampanel in Japanese Participants With Epilepsy

Phase 3 N=251 A Double-blind, Placebo-controlled Study of Levetiracetam in Epilepsy Patients With Generalized Tonic-clonic Seizures (Except Partial Seizures Evolving to Secondarily Generalized Seizures)

Phase 3 N=390 Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

Phase 3 N=605 A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures

Phase 4 N=38 Treatments for Psychogenic Nonepileptic Seizures (NES)

Phase 3 N=712 Evaluating Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures